Harpoon Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 104

Employees
  • Stock Symbol
  • HARP

Stock Symbol
  • Share Price
  • $2.14

  • (As of Monday Closing)

Harpoon Therapeutics General Information

Description

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 131 Oyster Point Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Harpoon Therapeutics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.14 $2.09 $1.73 - $9.94 $70.8M 33.1M 214K -$2.31

Harpoon Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV (37,473) 108,429 280,813 258,213
Revenue 23,018 23,654 17,444 5,777
EBITDA (73,890) (114,261) (48,857) (55,648)
Net Income (75,906) (116,721) (49,908) (55,572)
Total Assets 108,951 155,452 171,592 176,604
Total Debt 11,399 12,187 13,515 14,944
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Harpoon Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Harpoon Therapeutics‘s full profile, request access.

Request a free trial

Harpoon Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Harpoon Therapeutics‘s full profile, request access.

Request a free trial

Harpoon Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell
Drug Discovery
South San Francisco, CA
104 As of 2022
00000
00000000 00000

000000

met, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000000
Dallas, TX
000 As of 0000
00000
00000000 00000

000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000 000000000
San Carlos, CA
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Harpoon Therapeutics Competitors (93)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Instil Bio Formerly VC-backed Dallas, TX 000 00000 00000000 00000
00000000 Formerly VC-backed San Carlos, CA 00 00000 000000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
00000000 000000000 Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
You’re viewing 5 of 93 competitors. Get the full list »

Harpoon Therapeutics Patents

Harpoon Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220098311-A1 Flt3 binding proteins and methods of use Pending 21-Feb-2020 00000000000
US-20210261671-A1 Flt3 binding proteins and methods of use Granted 21-Feb-2020 000000000
US-11180563-B2 Flt3 binding proteins and methods of use Active 21-Feb-2020 000000000
JP-2022502371-A Pll3-binding protein and usage Pending 25-Sep-2018 000000000000
EP-3856771-A4 Dll3 binding proteins and methods of use Pending 25-Sep-2018 A61K39/39591
To view Harpoon Therapeutics’s complete patent history, request access »

Harpoon Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Julie Eastland Board Member & Chief Execuitve Officer
Georgia Erbez Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Holger Wesche Chief Scientific Officer
Karin Thacker Vice President, Regulatory Affairs and Quality Assurance
Che-Leung Law Ph.D Vice President of Translational Medicine
You’re viewing 5 of 9 executive team members. Get the full list »

Harpoon Therapeutics Board Members (14)

Name Representing Role Since
Alan Colowick MD Harpoon Therapeutics Board Member 000 0000
Andrew Robbins Harpoon Therapeutics Board Member 000 0000
Jo Viney Ph.D Self Board Member 000 0000
Jonathan Drachman MD Self Board Member 000 0000
Joseph Bailes Harpoon Therapeutics Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Harpoon Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial